Brokers Set Expectations for TPST Q1 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Tempest Therapeutics in a research report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.39) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempest Therapeutics has a consensus rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Stock Down 1.9%

Shares of NASDAQ:TPST opened at $1.59 on Thursday. Tempest Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $12.23. The firm’s 50-day simple moving average is $2.28 and its 200-day simple moving average is $5.10. The company has a market cap of $7.84 million, a price-to-earnings ratio of -0.24 and a beta of -2.00.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.62) EPS for the quarter, hitting analysts’ consensus estimates of ($0.62).

Insider Transactions at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Matthew Angel acquired 231,482 shares of the business’s stock in a transaction on Tuesday, March 24th. The stock was purchased at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at $500,001.12. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.28% of the company’s stock.

Hedge Funds Weigh In On Tempest Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics during the fourth quarter worth about $33,000. Finally, Sabby Management LLC acquired a new position in Tempest Therapeutics during the fourth quarter worth about $513,000. 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.